Type-switching of short-acting nicotine replacement therapy products and its implications for treatment.

What Was Tested

This observational study looks at Therapeutic nicotine (patch, non-peptide).

The researchers used discrete-time survival analysis to model the time elapsing before a change was made to another product and included time-by-product interactions to explore differences over time and product-by-previous-quit-attempts interactions to examine the importance of potential previous exposure to NRT.

Why It Was Studied

The frequency with which people change from one medical treatment to another partly reflects satisfaction with the initial intervention.

In this secondary analysis of observational data, the researchers explore switch rates for short-acting nicotine replacement therapy (NRT) products, which differ in mode of use, rapidity of action, and adverse effect profiles.

Who Took Part

The study group was 46,882 participants.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

The researchers analyzed data from 46,882 participants in the Smoking Treatment for Ontario Patients program who received short-acting NRT (gum, lozenge, oral spray, or inhaler) at their initial visit.

How the Study Was Run

The researchers adjusted both models for a range of sociodemographic and tobacco use variables.

What Was Measured

In this secondary analysis of observational data, the researchers explore switch rates for short-acting nicotine replacement therapy (NRT) products, which differ in mode of use, rapidity of action, and adverse effect profiles.

PubMed files the paper under topics including Tobacco Use Cessation Devices, Smoking Cessation, Ontario, Nicotine and Nicotine Replacement Therapy.

Author keywords: Adverse effects and Tolerability.

What This Means in Plain Language

This is an observational study of Therapeutic nicotine (patch, non-peptide) in 46,882 participants.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2024 (Journal of substance use and addiction treatment), a journal based in United States.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.